JW Pharmaceutical

JW중외제약 · 001060

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$453.9M (₩626.4B)

Overview

JW Pharmaceutical makes prescription medicines and other pharmaceutical products supplied to hospitals, clinics, and patients in Korea.

The company is listed on KOSPI, Korea's main stock exchange, and has operated as a mid-sized pharmaceutical business for decades. It consolidates five unlisted subsidiaries within its reported financials, reflecting a group structure built around its core drug business.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$561.8M

▲ +7.8% YoY

Operating profit · FY2025

US$68.4M

▲ +14.5% YoY

Net income · FY2025

US$44.6M

▼ −5.4% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$542.4M(₩748.5B)	US$521.3M(₩719.4B)	US$561.8M(₩775.3B)
Operating profit	US$72.7M(₩100.3B)	US$59.8M(₩82.5B)	US$68.4M(₩94.5B)
Net income	US$27.8M(₩38.4B)	US$47.1M(₩65B)	US$44.6M(₩61.5B)

Revenue

FY2023US$542.4M
FY2024US$521.3M
FY2025US$561.8M

Operating profit

FY2023US$72.7M
FY2024US$59.8M
FY2025US$68.4M

Net income

FY2023US$27.8M
FY2024US$47.1M
FY2025US$44.6M

Key ratios (FY2025)

ROE

16.6%

Debt/Eq

63.9%

Op. margin

12.2%

Net margin

7.9%

Rev. YoY

▲ +7.8%

Why it matters

JW Pharmaceutical classifies itself as a mid-sized enterprise under Korean corporate law, placing it in a category between a small business and a large conglomerate.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?